13Apr 2024
Enlivex Therapeutics Phase II Study: Positive Results for Allocetra in Sepsis Patients

Enlivex Therapeutics Phase II Study: Positive Results for Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. disclosed positive Phase II results for Allocetra in sepsis patients. The study highlighted Allocetra's promising safety profile and efficacy, particularly in cases originating from urinary tract infections. Despite higher initial severity in the treatment groups, lower mortality rates were observed. The company is considering further investigation, focusing on the high-risk UTI sepsis population, given the substantial market potential. Randomization challenges may require additional subgroup analysis for clearer interpretation.

  • #family health

Like

Save

Share